-Solia (desogestrel and ethinyl estradiol 0.15 mg/0.03 mg) Tablets will be the second generic oral contraceptive to the AB-rated brands Desogen® and Ortho-Cept® and will compete directly with the first generic, Apri®

Cincinnati, Ohio, June 14, 2004—Prasco Laboratories, a privately-held pharmaceutical company located in Cincinnati, Ohio, announced today it has begun shipping its first oral contraceptive Solia™1 (desogestrel and ethinyl estradiol 0.15 mg/0.03 mg) Tablets. Solia Tablets is a generic oral contraceptive to the AB-rated brands Desogen®2 and Ortho-Cept®3. Prasco expects Solia to compete directly with the first generic desogestrel and ethinyl estradiol 0.15 mg/0.03 mg product, Apri®4. For 2003, Apri had estimated sales of $121 million.5 “The launch of Solia is a result of our commitment to and focus on bringing to market best-in-class multi-source products in order to benefit pharmacists and consumers,” said Prasco Chief Executive Officer, E. Thomas Arington. “Solia will be marketed using our value-brand strategy, meaning the product will have brand quality, but priced like a generic. Prasco is pleased to provide an alternative to the other generic product in this market segment, and we look forward to launching additional value brands in other therapeutic categories during the second half of ‘04.”

About Prasco
Founded by Arington in 2002, Prasco’s mission is to provide both quality products and significant cost-savings to the consumer by becoming the leading marketer of multi-source products through selective partnerships. The company utilizes a versatile, horizontally-integrated business approach, which calls for Prasco to combine its intellectual property with the special capabilities of selected partners. Prasco’s partnering goal is to realizeopportunities and provide measurable results by finding and filling unmet needs within the pharmaceutical marketplace.

Prasco’s executive team has extensive experience working within both the brand and generic industries. A centerpiece of the company’s corporate capabilities is its sales/marketing and business development teams. Prasco’s product line is currently sold through the major distribution channels, including chains, wholesalers, and managed care providers. The company operates from a 54,000 sq. ft. administrative office and warehouse facility and has complete control over product distribution management systems—including a DEA-approved vault for chedule II-IV controlled substances.
1 Solia™ is a trademark of Prasco, LLC.
2 Desogen® is a registered trademark of Organon USA, Inc.
3 Ortho-Cept® is a registered trademark of Ortho-McNeil Pharmaceutical, Inc.
4 Apri® is a registered trademark of Barr Laboratories, Inc.
5 According to IMS data as of 5/25/04 8:43 am. Data on file. Prasco, LLC.

###

CONTACT:
Jeff Zurcher, Advisor to the Chairman, Communications
Prasco Laboratories
513-618-3333
website: www.prasco.com